Recent advances in the treatment of the seronegative spondyloarthropathies.
- 1 October 2001
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 3 (5) , 399-403
- https://doi.org/10.1007/s11926-996-0010-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Effect of a three month course of ciprofloxacin on the outcome of reactive arthritisAnnals of the Rheumatic Diseases, 2000
- Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot studyAnnals of the Rheumatic Diseases, 2000
- Methotrexate in the treatment of ankylosing spondylitisScandinavian Journal of Rheumatology, 2000
- Reactive arthritisCurrent Opinion in Rheumatology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- 5-Aminosalicylic Acid or Sulphapyridine1Drugs, 1986
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977